Recent Advances in the Treatment of Immune-Mediated Inflammatory Diseases

Methods Mol Biol. 2016;1371:143-55. doi: 10.1007/978-1-4939-3139-2_9.

Abstract

The treatment of immune-mediated inflammatory diseases (IMIDs) has dramatically improved over the last two decades by the development of a series of targeted biological therapies. This paper focuses on new developments in the treatment of IMIDs. In particular, we discuss how different ways of targeting the same mediators can lead to different efficacy and safety profiles, using B cell targeting as example. In addition, we discuss the emerging field of 'small molecules' that target specifically intracellular processes related to cytokine signaling, cell activation, cell migration, and other processes relevant to tissue inflammation.

Keywords: B cells; Immune-mediated inflammatory diseases; Signal transduction; Treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antigens, CD20 / metabolism
  • Antigens, Surface / metabolism
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • B-Lymphocytes / metabolism
  • Humans
  • Inflammation / drug therapy*
  • Inflammation / genetics
  • Inflammation / immunology*
  • Inflammation / metabolism
  • Janus Kinases / antagonists & inhibitors
  • MAP Kinase Signaling System / drug effects
  • NF-kappa B / antagonists & inhibitors
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antigens, CD20
  • Antigens, Surface
  • NF-kappa B
  • Protein Kinase Inhibitors
  • Janus Kinases